India’s generic-drug dominance is being squeezed as the US and Europe push for newer, tougher-to-manufacture molecules under stricter FDA compliance. Instead of building plants, Hyderabad-based HRV Pharma is banking on “drug visas,” or FDA DMFs that act as regulatory licenses for exporting active ingredients. The company, which owns no factories, operates in 55 countries and holds 66 DMFs, charging other manufacturers for the regulatory work—turning compliance into a scalable asset.
Generic semaglutide in India is expected to get dramatically cheaper, with prices likely to fall by more than half in the coming months. The drop is linked to the entry of smaller brands and a steep decline in raw material costs. A one month dose could fall to as low as ₹500, potentially widening access to the popular weight-loss drug.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
